Cynata Therapeutics Ltd has released a press release.
December 2025 Quarterly Activity Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Cynata Completes $1.2m At-The-Market Raise
- Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
- Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
- Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
- Final Patient Visit Complete in Phase 3 Osteoarthritis Trial
Later from Cynata Therapeutics
- Appendix 4D & Half-Year Financial Statements
- Last Visit in GvHD Trial Completed
- March 2026 Quarterly Activity Report & Appendix 4C
- Cynata Secures Commitments for $1.5m Placement
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics